NCT02366026View on ClinicalTrials.gov

REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study

PHASE3UnknownINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

June 30, 2017

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions
HIV
Interventions
BIOLOGICAL

IR103

REMUNE HIV/AIDS Vaccine with two adjuvants IFA + Amplivax

Trial Locations (1)

92101

Clinical Site TBA, San Diego

Sponsors
All Listed Sponsors
lead

Immune Response BioPharma, Inc.

INDUSTRY